AvalehtSTRO • NASDAQ
add
Sutro Biopharma Inc
Viimane sulgemishind
0,80 $
Tänane vahemik
0,77 $ - 0,82 $
Aasta vahemik
0,76 $ - 6,13 $
Turuväärtus
63,24 mln USD
Keskmine maht
1,76 mln
P/E suhe
-
Dividendimäär
-
Põhibörs
NASDAQ
Uudised
Finantsandmed
Kasumiaruanne
Käive
Puhastulu
| (USD) | dets 2024info | Y/Y muutus |
|---|---|---|
Käive | 14,81 mln | −86,98% |
Põhitegevusega seonduv kulu | 248,57 mln | 34,07% |
Puhastulu | −72,44 mln | −333,20% |
Puhaskasumimarginaal | −489,18 | −1 890,56% |
Puhaskasum aktsia kohta | −0,63 | −227,15% |
EBITDA | −63,39 mln | −241,23% |
Tõhus maksumäär | −3,36% | — |
Bilansiaruanne
Kogu vara
Kõik kohustused
| (USD) | dets 2024info | Y/Y muutus |
|---|---|---|
Sularaha ja lühiajalised investeeringud | 316,90 mln | −15,63% |
Kogu vara | 387,21 mln | −17,74% |
Kõik kohustused | 342,61 mln | 6,70% |
Kogu omakapital | 44,60 mln | — |
Emiteeritud aktsiate arv | 83,78 mln | — |
Hinna ja väärtuse suhe P/B | 1,47 | — |
Varade tasuvus | −38,89% | — |
Kapitali tasuvus | −160,07% | — |
Rahavoog
Raha ja raha ekvivalentide muutus
| (USD) | dets 2024info | Y/Y muutus |
|---|---|---|
Puhastulu | −72,44 mln | −333,20% |
Põhitegevuse rahakäive | −71,74 mln | −609,79% |
Investeeringute raha | 87,49 mln | 472,08% |
Finantseerimise raha | −24,00 tuh | 99,23% |
Raha ja raha ekvivalentide muutus | 15,73 mln | 225,15% |
Tasuta rahavoog | −45,47 mln | −245,86% |
Teave
Sutro Biopharma, Inc. is a publicly traded biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. William Newell, CEO as of 2024, joined Sutro in January 2009.
Sutro's cell-free protein synthesis and site-specific conjugation platform, XpressCF+, contributed to the discovery of STRO-001 and STRO-002, internally-developed antibody drug conjugates, or ADCs. STRO-001 is an ADC targeting CD74, a protein highly expressed in multiple myeloma and non-Hodgkin's lymphoma, and is currently in a Phase I clinical trial. STRO-002 is an ADC targeting folate receptor alpha, a cell-surface protein highly expressed in gynecological cancers. Wikipedia
Asutatud
2003
Veebisait
Töötajate arv
310
